
	Successor		Predecessor
(in millions of U.S. Dollars, except share data)	Three months ended March 29, 2026		Three months ended March 30, 2025
Net loss	$	(119.9)	$	(285.5)

Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic (in thousands)	39,282		153,897
Net loss per share attributable to common stockholders, basic	(3.05)		(1.86)

Net loss attributable to common stockholders, diluted	(119.9)		(285.5)









Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, diluted (in thousands)	39,282		153,897

Net loss per share attributable to common stockholders, diluted	$	(3.05)	$	(1.86)


	Successor		Predecessor
(in millions of U.S. Dollars, except share data)	Period from September 30, 2025 to March 29, 2026		Period from June 30, 2025 to September 29, 2025		Nine months ended March 30, 2025
Net (loss) income	$	(270.5)	$	420.2	$	(939.9)

Weighted-average number of shares outstanding used to compute net (loss) earnings per share attributable to common stockholders, basic (in thousands)	32,706		156,185		136,550
Net (loss) earnings per share attributable to common stockholders, basic	(8.27)		2.69		(6.88)

Net (loss) income attributable to common stockholders, diluted	(270.5)		420.2		(939.9)

Weighted-average number of shares outstanding used to compute net (loss) earnings per share attributable to common stockholders, basic (in thousands)	32,706		156,185		136,550
Weighted-average effect of potentially dilutive securities:


1.75% Convertible Notes	—		12,152		—
0.25% Convertible Notes	—		5,895		—
1.875% Convertible Notes	—		14,721		—
RSUs (Predecessor)	—		99		—
Weighted-average number of shares outstanding used to compute net (loss) earnings per share attributable to common stockholders, diluted (in thousands)	32,706		189,052		136,550

Net (loss) earnings per share attributable to common stockholders, diluted	$	(8.27)	$	2.22	$	(6.88)

Diluted net loss per share is the same as basic net loss per share for the periods presented due to potentially dilutive items being anti-dilutive given the Company's net loss. Weighted average number of shares of New Common Stock outstanding during the period computation includes shares of New Common Stock to be contractually issued as of the quarter end date and warrants exercisable for little or no consideration in relation to the share price.

For the three months ended March 29, 2026, the period from June 30, 2025 to September 29, 2025, and the period from September 30, 2025 to March 29, 2026, 64.2 million, 0.0 million and 64.3 million of weighted average shares, respectively, were excluded from the calculation of diluted loss per share because their effect would be anti-dilutive. For the three and nine months ended March 30, 2025, 6.4 million and 6.5 million of weighted average shares, respectively, were excluded from the calculation of diluted loss per share because their effect would be anti-dilutive.